Dermavant Sciences announced today that it dosed the first patient in a Phase 3 pivotal study of its atopic dermatitis (AD) treatment. Long Beach, California-based Dermavant’s double-blind, vehicle-controlled pivotal study evaluates tapinarof for the treatment of AD, according to a news release. The company developed tapinarof as an investigational novel, therapeutic aryl hydrocarbon receptor modulating […]
